Defilade Capital Management, L.P.
EMERYVILLE, CA · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$598.8M2026 Q3
Positions30
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.54.9%
What Changed This Quarter?
Top Holdings
PFE
Pfizer
7.3%
LLY
Eli Lilly
6.7%
BMRN
Biomarin Pharmaceutical
6.0%
GILD
Gilead Sciences
5.6%
AXSM
Axsome Therapeutics
5.4%
AMGN
Amgen
5.2%
ORIC
Oric Pharmaceuticals
5.1%
ASND
Ascendis Pharma A/S
4.9%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.